ISPOR - PGI15 COST PER REMISSION WITH VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF MODRATE TO SEVERELY ACTIVE CROHN'S DISEASE IN BRAZIL: PERSPECTIVE OF THE PRIVATE HEALTHCARE SYSTEM

PGI15 COST PER REMISSION WITH VEDOLIZUMAB AND USTEKINUMAB FOR THE TREATMENT OF MODRATE TO SEVERELY ACTIVE CROHN'S DISEASE IN BRAZIL: PERSPECTIVE OF THE PRIVATE HEALTHCARE SYSTEM

Abstract

Authors

C. Fioratti C. Regis E. Almeida

Full Text Cite This Article

Back to Volume 23, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now